[Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].
Bouza
E
E
Servicio de Microbiología Clínica, Unidad de Enfermedades Infecciosas-VIH, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid.
Rodríguez-Créixems
M
M
Muñoz
P
P
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects*; D017334:Teicoplanin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D014640:Vancomycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin